https://www.zacks.com/stock/news/2257704/merck-mrk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257704
Apr 18, 2024 - Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-6765914438041926935
0
https://www.zacks.com/stock/news/2257229/merck-mrk-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2257229
Apr 17, 2024 - In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.
zc:-7705631149562541353
0
https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375
Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
zc:4444330592211579728
0
https://www.zacks.com/stock/news/2253502/moderna-mrna-up-6-on-upbeat-data-from-cancer-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253502
Apr 10, 2024 - Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
zc:1207895086883196433
0
https://www.zacks.com/stock/news/2253234/company-news-for-apr-10-2024?cid=CS-ZC-FT-corporate_summary-2253234
Apr 10, 2024 - Companies in The News Are: MRNA, MRK, COIN, BN, NEOG
zc:-310375650857916554
0
https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285
Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
zc:4031363127901574233
0
https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526
Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
zc:8803092640589756350
0
https://www.zacks.com/stock/news/2248395/why-merck-mrk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2248395
Apr 01, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zc:8395635619522209438
0
https://www.zacks.com/stock/news/2247735/merck-mrk-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2247735
Mar 28, 2024 - Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.
zc:-7963822035858671630
0
https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400
Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
zc:-4251459591006756089
0